ClinicalTrials.gg
CompletedNCT00741819Updated Feb 20, 2013Results posted

Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects

A Phase 4 interventional study of Inhaled treprostinil in Pulmonary Arterial Hypertension, sponsored by United Therapeutics. Completed at 15 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-02-20.

Sponsored by United Therapeutics · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
73
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.

Enrollment
9th of 44
73 · median 32
Started
2008
with 3 others
Phase 4
14 of 44
1 open now
Registered
9th of 44
by date
Lead sponsor
32 of 44
United Therapeutics

Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 9th largest by enrollment, is one of 4 that started in 2008, is one of 14 in phase 4, and was the 9th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About treprostinil

treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing treprostinil in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

This is a 24-month, multi-center, prospective, open-label, safety evaluation in PAH subjects following transition from a stable dose of inhaled iloprost (Ventavis).

Subjects are to be evaluated for safety throughout the course of the study while secondary assessments will be conducted at Baseline, Week 6, Week 12, and Months 6, 12, 18 and 24 following initiation of treprostinil sodium.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • pulmonary arterial hypertension
  • PAH
  • treprostinil sodium
  • inhalation
  • ventavis
  • iloprost
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between 18 and 75 years of age
  • PAH diagnosis defined by following WHO Group I categories: idiopathic/familial, associated with unrepaired or repaired congenital systemic-to-pulmonary shunts (repaired >/= 5 years), associated with collagen vascular disease, associated with , associated with appetite suppressant/toxin use
  • Baseline six-minute walk distance (6MWD) >/= 250 meters
  • Currently receiving Ventavis and be stable at current dose for 30 days prior to Baseline
  • If currently receiving other approved background therapy (i.e. endothelin receptor antagonist or phosphodiesterase-5-inhibitor or both) must be on stable dose for 30 days prior to Baseline
  • Previous testing (e.g. right heart catheterization, echocardiography) consistent with diagnosis of PAH

Exclusion criteria

Exclusion Criteria:

  • Nursing or pregnant
  • Has acute concomitant disease (e.g. portal hypertension, chronic thromboembolic disease, pulmonary veno-occlusive disease, etc) other than those accepted as part of the inclusion criteria or has had atrial septostomy
  • History of uncontrolled sleep apnea, left-sided heart disease, or parenchymal lung disease
  • Use of drug within 30 days of Baseline
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    Inhaled treprostinil

    Solution for oral inhalation treprostinil (0.6 mg/mL). Inhaled via an ultrasonic nebulizer which provides a dose of 6mcg of treprostinil per breath. Doses are titrated up to 12 breaths four times daily.

    Drug: Inhaled treprostinil

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Adverse Events

    Overall safety of transitioning from inhaled iloprost to inhaled treprostinil was assessed by type and frequency of adverse events.

    Time frame: up to 24 months

Secondary outcomes

  1. Six-minute Walk Distance (6MWD)

    Change in 6MWD from Baseline to Week 12. The 6-minute walk test (6MWT) was conducted at Baseline (10-30 minutes following the last dose of inhaled iloprost) and at Week 12 (10-60 minutes following the dose of inhaled treprostinil). The change in distance (meters) between Baseline and Week 12 is reported below.

    Time frame: Baseline and 12 weeks

  2. Quality of Life (QoL) Assessment: Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR)

    Change in CAMPHOR Scores from Baseline to Week 12. The CAMPHOR is a health related quality of life instrument validated for pulmonary hypertension that assesses impairment (symptoms), disability (activities) and quality of life. The questionnaire is divided into three sections; Symptoms (Scores 0-25; high scores indicate more symptoms), Activity (Score 0-30; low score indicates good functioning)and Quality of Life (0-25; high scores indicate poor QoL). The sum of these scores equates to the Total score (0-80). In the CAMPHOR scores, lower scores indicate improvements.

    Time frame: Baseline and 12 weeks

  3. Treatment Satisfaction Questionnaire of Medication (TSQM)

    Change in TSQM score from Baseline to Week 12. The TSQM is a validated instrument (Health and Quality of Life Outcomes 2004, 2:12) that measures major dimensions of patient satisfaction with medications. The questionnaire is comprised of 15 questions which fall into one of four categories; Effectiveness, Side-Effects, Convenience, and Global Satisfaction. Responses are scaled on a seven point bipolar scale from 'Extremely Satisfied' to 'Extremely Dissatisfied' where higher scores indicate improvements (total scores from 0-100). The questionnaire was completed at Baseline and Week 12. The Baseline questionnaire focused on the subject's satisfaction with inhaled iloprost treatment, while the questionnaire completed at Week 12 focused on the subject's satisfaction with inhaled treprostinil.

    Time frame: Baseline and 12 weeks

  4. Patient Impression of Change

    The patient impression of change (PIC) was three single therapy-related questions related to the subjects overall impression of the transition from inhaled iloprost to inhaled treprostinil. Subjects were surveyed related to their overall impression of the transition from inhaled iloprost to inhaled treprostinil at Week 12.

    Time frame: Baseline and 12 weeks

  5. N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP)

    Change in NTpro-BNP from Baseline to Week 12. Blood samples were collected for plasma NTpro-BNP analysis during the study.

    Time frame: Baseline and Week 12

  6. World Health Organization (WHO) Functional Class

    Change in WHO Functional Class (FC) from Baseline to Week 12. Data presented as percent of subjects who either improved FC, worsened FC, or had no change in FC from Baseline to Week 12.

    Time frame: Baseline and 12 Weeks

  7. Drug Administration Activities Questionnaire

    Change in tasks from Baseline to Week 12. At Baseline and Week 12, subjects provided information related to the daily administration and time requirements of inhaled iloprost (Baseline) and inhaled treprostinil (Week 12).

    Time frame: Baseline and 12 weeks

07

Results

Posted Feb 20, 2013
Limitations and caveats
Small, open-label study without comparison arm.

Participant flow

Recruitment began 09-Dec-2008 and ended 09-Mar-2010. All recruitment took place in medical clinic settings.

Participant flow — Overall Study
MilestoneInhaled Treprostinil
Started73
Completed65
Not completed8
Withdrew: Adverse event3
Withdrew: Withdrawal by subject3
Withdrew: Death1
Withdrew: Disease progression1

Outcome measures

PrimaryNumber of Adverse Events

Overall safety of transitioning from inhaled iloprost to inhaled treprostinil was assessed by type and frequency of adverse events.

Time frame:
up to 24 months
Reported as:
Number · number of events
Number of Adverse Events
number of eventsInhaled Treprostinil
Overall events440
Possibly or Probably related events266
Severe events41
Serious events15
SecondarySix-minute Walk Distance (6MWD)

Change in 6MWD from Baseline to Week 12. The 6-minute walk test (6MWT) was conducted at Baseline (10-30 minutes following the last dose of inhaled iloprost) and at Week 12 (10-60 minutes following the dose of inhaled treprostinil). The change in distance (meters) between Baseline and Week 12 is reported below.

Time frame:
Baseline and 12 weeks
Reported as:
Median · meters
Six-minute Walk Distance (6MWD)
metersInhaled Treprostinil
Week 12392.5 (220 to 708)
Change from Baseline16 ± 78
Statistical analysis
  • Inhaled Treprostinil · Wilcoxon signed rank test] · p = <0.001 · Median difference (final values): 16Change in 6MWD from Baseline was calculated for patients still remaining on study at Week 12.
SecondaryQuality of Life (QoL) Assessment: Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR)

Change in CAMPHOR Scores from Baseline to Week 12. The CAMPHOR is a health related quality of life instrument validated for pulmonary hypertension that assesses impairment (symptoms), disability (activities) and quality of life. The questionnaire is divided into three sections; Symptoms (Scores 0-25; high scores indicate more symptoms), Activity (Score 0-30; low score indicates good functioning)and Quality of Life (0-25; high scores indicate poor QoL). The sum of these scores equates to the Total score (0-80). In the CAMPHOR scores, lower scores indicate improvements.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · units on a scale
Quality of Life (QoL) Assessment: Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR)
units on a scaleInhaled Treprostinil
Symptom Score at Week 125.3 (0 to 21)
Change in Symptom Score-2.9 ± 3.9
Activity Score at Week 126.6 (0 to 16)
Change in Activity Score-1.2 ± 2.5
Quality of Life Score at Week 124.9 (0 to 20)
Change in Quality of Life Score-2.4 ± 3.9
Total Score at Week 1216.8 (0 to 53)
Change in Total Score-6.4 ± 7.7
Statistical analysis
  • Inhaled Treprostinil · Wilcoxon signed rank test · p = <0.001 · Mean difference (final values): -6.4Analysis based on Total CAMPHOR Score.
SecondaryTreatment Satisfaction Questionnaire of Medication (TSQM)

Change in TSQM score from Baseline to Week 12. The TSQM is a validated instrument (Health and Quality of Life Outcomes 2004, 2:12) that measures major dimensions of patient satisfaction with medications. The questionnaire is comprised of 15 questions which fall into one of four categories; Effectiveness, Side-Effects, Convenience, and Global Satisfaction. Responses are scaled on a seven point bipolar scale from 'Extremely Satisfied' to 'Extremely Dissatisfied' where higher scores indicate improvements (total scores from 0-100). The questionnaire was completed at Baseline and Week 12. The Baseline questionnaire focused on the subject's satisfaction with inhaled iloprost treatment, while the questionnaire completed at Week 12 focused on the subject's satisfaction with inhaled treprostinil.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · units on a scale
Treatment Satisfaction Questionnaire of Medication (TSQM)
units on a scaleInhaled Treprostinil
Effectiveness Score at Week 1281.9 (44 to 100)
Change in Effectiveness Score19.9 ± 21.5
Side-effects Score at Week 1284.4 (25 to 100)
Change in Side-Effects Score-0.5 ± 21.3
Convenience Score at Week 1283.3 (33 to 100)
Change in Convenience Score38.3 ± 25.9
Global Satisfaction Score at Week 1281.9 (36 to 100)
Change in Global Satisfaction20.0 ± 23.7
Statistical analysis
  • Inhaled Treprostinil · Wilcoxon signed-rank test · p = 0.895 · Mean difference (final values): -0.5Side-Effects Score, change from Baseline to Week 12
  • Inhaled Treprostinil · Wilcoxon signed-rank test · p = <0.001 · Mean difference (final values): 38.3Convenience Score, change from Baseline to Week 12
  • Inhaled Treprostinil · Wilcoxon signed-rank test · p = <0.001 · Mean difference (final values): 20.0Global Satisfaction, change from Baseline to Week 12
  • Inhaled Treprostinil · Wilcoxon signed rank test · p = <0.001 · Mean difference (final values): 19.9Effectiveness score, change from Baseline to Week 12
SecondaryPatient Impression of Change

The patient impression of change (PIC) was three single therapy-related questions related to the subjects overall impression of the transition from inhaled iloprost to inhaled treprostinil. Subjects were surveyed related to their overall impression of the transition from inhaled iloprost to inhaled treprostinil at Week 12.

Time frame:
Baseline and 12 weeks
Reported as:
Number · percentage of patients
Patient Impression of Change
percentage of patientsInhaled Treprostinil
Improvement of Symptoms73 ± 80.5
Improvment in Time Spent91
Overall Satisfaction94
SecondaryN-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP)

Change in NTpro-BNP from Baseline to Week 12. Blood samples were collected for plasma NTpro-BNP analysis during the study.

Time frame:
Baseline and Week 12
Reported as:
Median · pg/mL
N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP)
pg/mLInhaled Treprostinil
N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP)-74 (-4728 to 3837)
Statistical analysis
  • Inhaled Treprostinil · Wilcoxon signed-rank test · p = 0.001
SecondaryWorld Health Organization (WHO) Functional Class

Change in WHO Functional Class (FC) from Baseline to Week 12. Data presented as percent of subjects who either improved FC, worsened FC, or had no change in FC from Baseline to Week 12.

Time frame:
Baseline and 12 Weeks
Reported as:
Number · percentage of subjects
World Health Organization (WHO) Functional Class
percentage of subjectsInhaled Treprostinil
Improvement6
No Change87
Worsened7
SecondaryDrug Administration Activities Questionnaire

Change in tasks from Baseline to Week 12. At Baseline and Week 12, subjects provided information related to the daily administration and time requirements of inhaled iloprost (Baseline) and inhaled treprostinil (Week 12).

Time frame:
Baseline and 12 weeks
Reported as:
Mean · minutes
Drug Administration Activities Questionnaire
minutesInhaled Treprostinil
Week 12 Total Daily Dosing Time39.1 ± 25.1
Change in Time Total Daily Dosing Time-79.3 ± 80.5

Adverse events

Collected over up to 56 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Inhaled Treprostinil—10/73 (13.7%)71/73 (97.3%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventInhaled Treprostinil
PneumoniaInfections and infestations2/73
Pulmonary hypertensionCardiac disorders2/73
Cor pulmonaleCardiac disorders1/73
AsthmaRespiratory, thoracic and mediastinal disorders1/73
Atrial fibrillationCardiac disorders1/73
DehydrationMetabolism and nutrition disorders1/73
gastrointestinal hemorrhageGastrointestinal disorders1/73
InfluenzaInfections and infestations1/73
Myocardial infarctionCardiac disorders1/73
Sick sinus syndromeCardiac disorders1/73
Most frequent other events
Showing 10 of 25
Most frequent other events
EventInhaled Treprostinil
CoughRespiratory, thoracic and mediastinal disorders54/73
HeadacheNervous system disorders32/73
NauseaGastrointestinal disorders22/73
Chest discomfortGeneral disorders12/73
upper respiratory tract infectionInfections and infestations11/73
nasopharyngitisRespiratory, thoracic and mediastinal disorders11/73
flushingVascular disorders11/73
dizzinessNervous system disorders10/73
palpitationsCardiac disorders9/73
throat irritationRespiratory, thoracic and mediastinal disorders9/73

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Inhaled Treprostinil
<=18 years0
Between 18 and 65 years63
>=65 years10
Age Continuous
Age Continuous(years)Inhaled Treprostinil
Mean49.4 ± 12.6
Sex: Female, Male
Sex: Female, Male(Participants)Inhaled Treprostinil
Female57
Male16
Region of Enrollment
Region of Enrollment(participants)Inhaled Treprostinil
United States73
Pulmonary Arterial Hypertension (PAH) etiology
Pulmonary Arterial Hypertension (PAH) etiology(participants)Inhaled Treprostinil
Idiopathic PAH or familial PAH35
Connective Tissue Diseases (CTD)16
Congenital heart disease (CHD)-repaired shunt4
CHD-unrepaired shunt15
HIV3
Background PAH therapy
Background PAH therapy(participants)Inhaled Treprostinil
None3
Endothelin receptor antagonist (ERA)19
Phosphodiesterase-5 inhibitor (PDE-5i)8
ERA and PDE-5i43
Six-minute walk distance (6MWD)
Six-minute walk distance (6MWD)(meters)Inhaled Treprostinil
Median378 ± 78
N-terminal prohormone brain natriuretic peptide (NT-proBNP)
N-terminal prohormone brain natriuretic peptide (NT-proBNP)(pg/mL)Inhaled Treprostinil
Median626 (26 to 8324)
08

Study locations

15 sites
  • University of Alabama Birmingham
    Birmingham, Alabama 35294, United States
  • UCSD Medical Center
    La Jolla, California 82037, United States
  • Ronald Reagan UCLA Medical Center
    Los Angeles, California 90095, United States
  • Kansas University Medical Center
    Kansas City, Kansas 66160, United States
  • Long Island Jewish Medical Center - North Shore
    New Hyde Park, New York 11040, United States
  • Beth Israel Medical Center
    New York City, New York 10003-3314, United States
  • Cornell University Medical Center
    New York City, New York 10021, United States
  • Columbia Presbyterian Medical Center
    New York, New York 10032, United States
  • Mary M. Parkes Center for Asthma, Allergy and Pulmonary Care
    Rochester, New York 14623, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Ohio State University Medical Center
    Columbus, Ohio 43210, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • University of Pittsburg Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Mar 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2013, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2008
First posted
Aug 26, 2008
Start
Sep 2008
Primary completionActual
Mar 2010
CompletionActual
Dec 2010
Results first posted
Feb 20, 2013
Last update
Feb 20, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00741819
Responsible party
Sponsor
First posted
Aug 26, 2008
Start date
Sep 2008
Primary completion
Mar 2010
Completion
Dec 2010
Results posted
Feb 20, 2013
Last update
Feb 20, 2013

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion